Effects of short-term varenicline administration on emotional and cognitive processing in healthy, non-smoking adults: A randomized, double-blind, study

Neuropsychopharmacology

Volumn 38, Issue 3, 2013, Pages 476-484

  Mocking, Roel J T ^a,b   Patrick Pflanz, C ^a,c   Pringle, Abbie ^a   Parsons, Elizabeth ^a   McTavish, Sarah F ^a   Cowen, Phil J ^a   Harmer, Catherine J ^a  

^a WARNEFORD HOSPITAL   (United Kingdom)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c UNIVERSITY OF COLOGNE   (Germany)

Author keywords

adverse effects; depression; nicotinic agonists; randomized controlled trial; smoking cessation; tobacco use cessation products

Indexed keywords

PLACEBO; VARENICLINE;

ADULT; ARTICLE; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; DECLARATIVE MEMORY; DOUBLE BLIND PROCEDURE; EMOTION; FACIAL EXPRESSION; FEMALE; HUMAN; IMPULSIVENESS; LATENT PERIOD; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECALL; SMOKING CESSATION; STARTLE REFLEX; TREATMENT DURATION; WORKING MEMORY;

ADOLESCENT; ADULT; BENZAZEPINES; COGNITION; DOUBLE-BLIND METHOD; EMOTIONS; FEMALE; HEALTH STATUS; HUMANS; MALE; NICOTINIC AGONISTS; QUESTIONNAIRES; QUINOXALINES; REACTION TIME; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84872492343     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2012.205     Document Type: Article

References (49)

1. Beck AT, Steer RA, Ball R, Ranieri W (1996). Comparison of Beck depression inventories -IA and -II in psychiatric outpatients. J Pers Assess 67: 588-597.
2. Cahill K, Stead LF, Lancaster T (2011). Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 16: CD006103.
3. Cocores JA, Gold MS (2008). Varenicline and adult ADHD. J Neuropsychiatry ClinNeurosci 20: 494-495.
4. Covey LS, Glassman AH, Stetner F (1990). Depression and depressive symptoms in smoking cessation. Compr Psychiatry 31: 350-354.
5. Crawford JR, Henry JD (2004). The positive and negative affect schedule (PANAS): construct validity, measurement properties and normative data in a large non-clinical sample. Br J Clin Psychol 43(Pt3): 245-265.
6. Dougherty DM, Marsh DM, Mathias CW (2002). Immediate and delayed memory tasks: a computerized behavioral measure of memory, attention, and impulsivity. Behav Res Methods Instrum Comput 34: 391-398.
7. Ekman P, Friesen WV (1976). Pictures of Facial Affect. Consulting Psychologists Press: Palo Alto, CA.
8. Eysenck HJ, Eysenck SBG (1975). Manual of the Eysenck personality questionnaire. Hodderand Stoughton, London.
9. Faessel HM, Smith BJ, Gibbs MA, Gobey JS, Clark DJ, Burstein AH (2006). Single-dose pharmacokinetics of varenicline, a selective nicotinic receptor partial agonist, in healthy smokers and nonsmokers. J Clin Pharmacol 46: 991-998.
10. Faessel HM, Obach RS, Rollema H, Ravva P, Williams KE, Burstein AH (2010). A review of the clinical pharmacokinetics and pharmacodynamics of varenicline for smoking cessation. Clin Pharmacokinet 49: 799-816.
11. First MB, Spitzer RL, Gibbon M, Williams JB (1997). User's guide for the Structured Clinical Interview for DSM-IV Axis I Disorders SCID-I: Clinician Version. American's Psychiatric Publishing: Arlington.
12. Garza D, Murphy M, Tseng LJ, Riordan HJ, Chatterjee A (2011). A double-blind randomized placebo-controlled pilot study of neuropsychiatric adverse events in abstinent smokers treated with varenicline or placebo. Biol Psychiatry 69: 1075-1082.
13. Ginani G, Tufik S, Bueno O, Pradella-Hallinan M, Rusted J, Pompéia S (2011). Acute effects of donepezil in healthy young adults underline the fractionation of executive functioning. J Psychopharmacol 25: 1508-1516.
14. Grier JB (1971). Nonparametric indexes for sensitivity and bias: computing formulas. Psychol Bull 75: 424-429.
15. Harmer CJ, Cowen PJ, Goodwin GM (2011). Efficacy markers in depression. J Psychopharmacol 25: 1148-1158.
16. Harrison-Woolrych M, Ashton J (2011). Psychiatric adverse events associated with varenicline: an intensive postmarket-ing prospective cohort study in New Zealand. Drug Saf 34: 763-772.
17. Hayward G, Goodwin GM, Cowen PJ, Harmer CJ (2005). Low-dose tryptophan depletion in recovered depressed patients induces changes in cognitive processing without depressive symptoms. Biol Psychiatry 57: 517-524.
18. Hong LE, Thaker GK, McMahon RP, Summerfelt A, Rachbeisel J, Fuller RL et al (2011). Effects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizo-phrenia or schizoaffective disorder. Arch Gen Psychiatry 68: 1195-1206.
19. Horder J, Browning M, Di Simplicio M, Cowen PJ, Harmer CJ (2012). Effects of 7 days treatment with the cannabinoid type 1 receptor antagonist, rimonabant, on emotional processing. J Psychopharmacol 26: 125-132.
20. Larson CL, Ruffalo D, Nietert JY, Davidson RJ (2000). Temporal stability of the emotion-modulated startle response. Psychophy-siology 37: 92-101.
21. Laviolette SR, van der Kooy D (2004). The neurobiology of nicotine addiction: bridging the gap from molecules to behaviour. Nat Rev Neurosci 5: 55-65.
22. Lawrence D, Mitrou F, Zubrick SR (2009). Smoking and mental illness: results from population surveys in Australia and the United States. BMC Public Health 9: 285.
23. Loughead J, Ray R, Wileyto EP, Ruparel K, Sanborn P, Siegel S et al (2010). Effects of the alpha4beta2 partial agonist varenicline on brain activity and working memory in abstinent smokers. Biol Psychiatry 67: 715-721.
24. Mannie ZN, Harmer CJ, Cowen PJ, Norbury R (2010). A functional magnetic resonance imaging study ofverbal working memory in young people at increased familial risk of depression. Biol Psychiatry 67: 471-477.
25. Medicines and Healthcare Products Regulatory Agency (2008). Varenicline: safety update. Drug Safety Update 1: 3-4.
26. Mineur YS, Picciotto MR (2010). Nicotine receptors and depression: revisiting and revising the cholinergic hypothesis. Trends Pharmacol Sci 31: 580-586.
27. Moore TJ, Furberg CD, Glenmullen J, Maltsberger JT, Singh S (2011). Suicidal behavior and depression in smoking cessation treatments. PLoS One 6: e27016.
28. National Center for Chronic Disease Prevention and Health Promotion (2011). Tobacco use, targeting the nation's leading killer. http://www.cdc.gov/ chronicdisease/resources/publications/aag/pdf/2011/Tobacco-AAG-2011-508.pdf.
29. Ohmura Y, Tsutsui-Kimura I, Yoshioka M (2012). Impulsive behavior and nicotinic acetylcholine receptors. J Pharmacol Sci 118: 413-422.
30. O'Malley SS (2011). Varenicline and the evaluation of neuropsy-chiatric adverse events in smokers. BiolPsychiatry 69: 1017-1018.
31. Oncken C, Gonzales D, Nides M, Rennard S, Watsky E, Billing CB et al (2006). Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med 166: 1571-1577.
32. Patterson F, Jepson C, Strasser AA, Loughead J, Perkins KA, Gur RC et al (2009). Varenicline improves mood and cognition during smoking abstinence. Biol Psychiatry 65: 144-149.
33. Patterson F, Jepson C, Loughead J (2010). Working memory deficits predict short-term smoking resumption following brief abstinence. Drug Alcohol Depend 106: 61-64.
34. Philip NS, Carpenter LL, Tyrka AR, Whiteley LB, Price LH (2009). Varenicline augmentation in depressed smokers: an 8-week, open-label study. J Clin Psychiatry 70: 1026-1031.
35. Philip NS, Carpenter LL, Tyrka AR, Price LH (2010). Nicotinic acetylcholine receptors and depression: a review of the preclinical and clinical literature. Psychopharmacology (Berl) 212: 1-12.
36. Picciotto MR, Zoli M, Rimondini R, Léna C, Marubio LM, Pich EM et al (1998). Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine. Nature 391: 173-177.
37. Potter AS, Bucci DJ, Newhouse PA (2012). Manipulation of nicotinic acetylcholine receptors differentially affects behavioral inhibition in human subjects with and without disordered baseline impulsivity. Psychopharmacology (Berl) 220: 331-340.
38. Pringle A, Browning M, Cowen PJ, Harmer CJ (2011a). A cognitive neuropsychological model of antidepressant drug action. Prog Neuropsychopharmacol Biol Psychiatry 35: 1586-1592.
39. Pringle A, McTavish SF, Williams C, Smith R, Cowen PJ, Harmer CJ (2011b). Short-term NK1 receptor antagonism and emotional processing in healthy volunteers. Psychopharmacology (Berl) 215: 239-246.
40. Rey A (1964). L'examen de Clinique en Psychologie. Presses Universitaires de France: Paris.
41. Rollema H, Chambers LK, Coe JW, Glowa J, Hurst RS, Lebel LA et al (2007). Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology 52: 985-994.
42. Rokem A, Landau AN, Garg D, Prinzmetal W, Silver MA (2010). Cholinergic enhancement increases the effects of voluntary attention but does not affect involuntary attention. Neuropsy-chopharmacology 35: 2538-2544.
43. Sofuoglu M (2010). Cognitive enhancement as a pharmacotherapy target for stimulant addiction. Addiction 105: 38-48.
44. Spielberger CD, Gorssuch RL, Lushene PR, Vagg PR, Jacobs GA (1983). Manualfor the State-Trait Anxiety Inventory. Consulting Psychologists Press: White Bear Lake.
45. Tapper AR, McKinney SL, Nashimi R, Schwarz J, Deshpande P, Labarca C et al (2004). Nicotine activation of α4 receptors: sufficient for reward, tolerance, and sensitization. Science 306: 1029-1032.
46. Tonstad S, Davies S, Flammer M, Russ C, Hughes J (2010). Psychiatric adverse events in randomized, double-blind, place-bo-controlled clinical trials of varenicline: a pooled analysis. DrugSaf33: 289-301.
47. Tsutsui-Kimura I, Ohmura Y, Izumi T, Yamaguchi T, Yoshida T, Yoshioka M (2010). Endogenous acetylcholine modulates impulsive action via alpha4beta2 nicotinic acetylcholine recep-tors in rats. Eur J Pharmacol 641: 148-153.
48. Von Zerssen D, Petermann F (2011). Bf-SR - Die Befindlichkeits-Skala - Revidierte Fassung. Hogrefe: Göttingen.
49. Williams JM, Steinberg MB, Steinberg ML, Gandhi KK, Ulpe R, Foulds J (2011). Varenicline for tobacco dependence: panacea or plight? Expert Opin Pharmacother 12: 1799-1812.